No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
News, Urological Disorders
A list of medications routinely prescribed in primary care practice that should be used cautiously or avoided in patients with chronic kidney disease (CKD) was compiled in a recently published study in the Annals of Pharmacotherapy.
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
To shed light on this complex subject, MPR interviewed Joshua D Brown, PharmD, PhD, Assistant Professor, Pharmaceutical Outcomes & Policy.
The World Health Organization (WHO) has updated the WHO Model List of Essential Medicines for 2019.
The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source
According to the findings of a recent study, attorney advertisements appear to influence patients’ decisions on modifying or discontinuing their direct oral anticoagulant (DOAC) medication prior to seeking medical advice.
For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.